When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Access to genomic testing, not therapy cost, is the biggest challenge
Highlighting KEYTRUDA & expanding cancer pipeline
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Pharma giant targets new standards of care
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
Subscribe To Our Newsletter & Stay Updated
